HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CD36
CD36 molecule (CD36 blood group)
Chromosome 7 Β· 7q21.11
NCBI Gene: 948Ensembl: ENSG00000135218.19HGNC: HGNC:1663UniProt: A4D1B1
546PubMed Papers
22Diseases
0Drugs
53Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneReceptorTransporter
RESEARCH IMPACT
Highly StudiedTrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
amyloid-beta clearance by cellular catabolic processamyloid-beta bindinglow-density lipoprotein particle receptor activityscavenger receptor activityplatelet-type bleeding disorder 10cardiomyopathyinherited bleeding disorder, platelet-typecoronary artery disease
✦AI Summary

CD36 is a multifunctional transmembrane scavenger receptor that serves as the primary mediator of long-chain fatty acid uptake across cell membranes 1. Beyond lipid transport, CD36 binds diverse ligands including thrombospondin-1, apoptotic cells, and pathogen-associated molecular patterns, enabling roles in inflammation, immunological recognition, and molecular adhesion 2. CD36 functions as a critical fatty acid sensor that coordinates fat utilization through oral fat perception, intestinal absorption, and regulation of hepatic lipoprotein output 3. In cardiovascular disease, CD36 expression is dysregulated across multiple pathologies: decreased in ischaemia-reperfusion injury but increased in diabetic cardiomyopathy and atherosclerosis 1. CD36 also plays complex roles in liver pathophysiology, participating in lipid metabolism, inflammation, and oxidative stress relevant to fatty liver disease, NASH, fibrosis, and hepatic malignancy 4. CD36 has emerged as a significant oncologic target. In cancer, CD36-driven lipid metabolic reprogramming promotes metastatic initiation and therapy resistance, with metastasis-initiating cells showing high CD36 expression enhanced by dietary palmitic acid 5. In the tumor microenvironment, CD36-mediated fatty acid uptake by CD8+ T cells induces ferroptosis and immunotolerance, while CD36 inhibition restores antitumor immunity 6. Recent evidence identifies CD36 as a downstream target in colorectal cancer progression via the PLIN2/CD36 axis regulating epithelial-mesenchymal transition 7.

Sources cited
1
CD36 mediates long-chain fatty acid uptake and is dysregulated in cardiovascular diseases including ischaemia-reperfusion injury, diabetic cardiomyopathy, and atherosclerosis
PMID: 33210138
2
CD36 is a scavenger receptor mediating lipid uptake, immunological recognition, inflammation, molecular adhesion, and apoptosis; binds thrombospondin-1 and fatty acids
PMID: 31410189
3
CD36 functions as a high-affinity fatty acid transporter and regulator of lipid metabolism; coordinates fat utilization through oral fat perception, intestinal absorption, and hepatic lipoprotein regulation
PMID: 24850384
4
CD36 participates in liver pathophysiology through roles in lipid metabolism, inflammation, and oxidative stress in nonalcoholic fatty liver disease, NASH, fibrosis, and liver cancer
PMID: 39774047
5
CD36+ metastasis-initiating cells are enhanced by dietary lipids and high-fat diet; CD36 blockade inhibits metastasis in oral, melanoma, and breast cancers
PMID: 27974793
6
CD36-mediated fatty acid uptake by tumor-infiltrating CD8+ T cells induces ferroptosis and reduces antitumor cytokine production; CD36 inhibition restores T cell function and enhances anti-PD-1 efficacy
PMID: 33691090
7
CD36 is a critical fatty acid sensor and regulator of lipid metabolism relevant to metabolic diseases and obesity
PMID: 36055468
8
CD36 is a downstream target of PLIN2 in colorectal cancer; PLIN2 stabilizes CD36 protein to promote epithelial-mesenchymal transition and cancer progression
PMID: 40640171
Disease Associationsβ“˜22
platelet-type bleeding disorder 10Open Targets
0.74Strong
cardiomyopathyOpen Targets
0.45Moderate
inherited bleeding disorder, platelet-typeOpen Targets
0.41Moderate
coronary artery diseaseOpen Targets
0.39Weak
inborn error of immunityOpen Targets
0.37Weak
ThromboembolismOpen Targets
0.34Weak
atrial fibrillationOpen Targets
0.34Weak
ThalassemiaOpen Targets
0.26Weak
physical activityOpen Targets
0.24Weak
ThrombocytopeniaOpen Targets
0.22Weak
exostosisOpen Targets
0.18Weak
response to antihypertensive drugOpen Targets
0.16Weak
adolescent idiopathic scoliosisOpen Targets
0.16Weak
osteopetrosisOpen Targets
0.15Weak
skin diseaseOpen Targets
0.15Weak
neoplasmOpen Targets
0.12Weak
Premature coronary artery atherosclerosisOpen Targets
0.12Weak
breast cancerOpen Targets
0.12Weak
non-small cell lung carcinomaOpen Targets
0.11Weak
cancerOpen Targets
0.11Weak
Coronary heart disease 7UniProt
Platelet glycoprotein IV deficiencyUniProt
Pathogenic Variants53
NM_001001548.3(CD36):c.784dup (p.Gln262fs)Pathogenic
Malaria, susceptibility to|Platelet-type bleeding disorder 10
β˜…β˜…β˜†β˜†2025β†’ Residue 262
NM_001001548.3(CD36):c.667_671del (p.Lys223fs)Pathogenic
CD36-related disorder|Platelet-type bleeding disorder 10
β˜…β˜…β˜†β˜†2025β†’ Residue 223
NM_001001548.3(CD36):c.729C>A (p.Cys243Ter)Pathogenic
Platelet-type bleeding disorder 10
β˜…β˜…β˜†β˜†2024β†’ Residue 243
NM_001001548.3(CD36):c.1206_1230dup (p.Val411fs)Likely pathogenic
Platelet-type bleeding disorder 10|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 411
NM_001001548.3(CD36):c.1240_1243dup (p.Trp415fs)Pathogenic
Platelet-type bleeding disorder 10
β˜…β˜…β˜†β˜†2024β†’ Residue 415
NM_001001548.3(CD36):c.430-2A>GLikely pathogenic
Platelet-type bleeding disorder 10|Malaria, susceptibility to;Coronary heart disease, susceptibility to, 7;Platelet-type bleeding disorder 10|Melanoma
β˜…β˜…β˜†β˜†2024
NM_001001548.3(CD36):c.1228_1239del (p.Ile410_Ile413del)Pathogenic
Platelet-type bleeding disorder 10|CD36-related disorder
β˜…β˜…β˜†β˜†2023β†’ Residue 410
NM_001001548.3(CD36):c.1195del (p.Ile399fs)Pathogenic
not provided|CD36-related disorder|Platelet-type bleeding disorder 10
β˜…β˜…β˜†β˜†2023β†’ Residue 399
NM_001001548.3(CD36):c.1254+1G>ALikely pathogenic
Platelet-type bleeding disorder 10;Coronary heart disease, susceptibility to, 7;Malaria, susceptibility to|Platelet-type bleeding disorder 10|CD36-related disorder|not provided
β˜…β˜…β˜†β˜†2023
NM_001001548.3(CD36):c.332_333del (p.Thr111fs)Pathogenic
Platelet-type bleeding disorder 10|Coronary heart disease, susceptibility to, 7;Malaria, susceptibility to;Platelet-type bleeding disorder 10
β˜…β˜…β˜†β˜†2023β†’ Residue 111
NM_001001548.3(CD36):c.186C>G (p.Tyr62Ter)Likely pathogenic
Platelet-type bleeding disorder 10
β˜…β˜…β˜†β˜†2023β†’ Residue 62
NM_001001548.3(CD36):c.1150del (p.Ala384fs)Likely pathogenic
Platelet-type bleeding disorder 10|not provided
β˜…β˜…β˜†β˜†2022β†’ Residue 384
NM_001001548.3(CD36):c.1156C>T (p.Arg386Trp)Likely pathogenic
Platelet-type bleeding disorder 10|not provided|CD36-related disorder
β˜…β˜…β˜†β˜†2022β†’ Residue 386
NM_001001548.3(CD36):c.1142T>G (p.Leu381Ter)Pathogenic
Platelet-type bleeding disorder 10|Platelet-type bleeding disorder 10;Malaria, susceptibility to;Coronary heart disease, susceptibility to, 7
β˜…β˜…β˜†β˜†2020β†’ Residue 381
NM_001001548.3(CD36):c.949dup (p.Ile317fs)Likely pathogenic
Platelet-type bleeding disorder 10
β˜…β˜…β˜†β˜†2020β†’ Residue 317
NM_001001548.3(CD36):c.429+1G>ALikely pathogenic
CD36-related disorder|Platelet-type bleeding disorder 10|Acute myeloid leukemia|Clear cell carcinoma of kidney
β˜…β˜†β˜†β˜†2025
NM_001001548.3(CD36):c.15del (p.Asn6fs)Pathogenic
CD36-related disorder
β˜…β˜†β˜†β˜†2025β†’ Residue 6
NM_001001548.3(CD36):c.818+1G>TLikely pathogenic
Platelet-type bleeding disorder 10
β˜…β˜†β˜†β˜†2025
NM_001001548.3(CD36):c.667_671dup (p.Ala225fs)Pathogenic
Platelet-type bleeding disorder 10
β˜…β˜†β˜†β˜†2024β†’ Residue 225
NM_001001548.3(CD36):c.1062_1098dup (p.His367delinsArgThrTyrTer)Pathogenic
CD36-related disorder
β˜…β˜†β˜†β˜†2024β†’ Residue 367
View on ClinVar β†—
Related Genes
GP2Protein interaction100%S100A9Protein interaction100%LY96Protein interaction100%CLEC7AProtein interaction100%IL13Protein interaction99%ABCA1Protein interaction98%
Tissue Expression6 tissues
Heart
100%
Bone Marrow
14%
Lung
13%
Liver
2%
Ovary
0%
Brain
0%
Gene Interaction Network
Click a node to explore
CD36GP2S100A9LY96CLEC7AIL13ABCA1
PROTEIN STRUCTURE
Preparing viewer…
PDB5LGD Β· 2.07 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.95LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF1.69 [1.26–1.95]
RankingsWhere CD36 stands among ~20K protein-coding genes
  • #455of 20,598
    Most Researched546 Β· top 5%
  • #1,272of 5,498
    Most Pathogenic Variants53 Β· top quartile
  • #17,689of 17,882
    Most Constrained (LOEUF)1.95
Genes detectedCD36
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
The role of CD36 in cardiovascular disease.
PMID: 33210138
Cardiovasc Res Β· 2022
1.00
2
CD36-mediated ferroptosis dampens intratumoral CD8
PMID: 33691090
Cell Metab Β· 2021
0.90
3
CD36 inhibits Ξ²-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis.
PMID: 31484922
Nat Commun Β· 2019
0.82
4
CD36 tango in cancer: signaling pathways and functions.
PMID: 31410189
Theranostics Β· 2019
0.80
5
CD36 and atherosclerosis.
PMID: 11048891
Curr Opin Lipidol Β· 2000
0.78